Topic: patent settlements
Boehringer fought hard against AbbVie’s Humira “patent thicket." But in the end, the German company settled, just like its fellow biosim challengers.
Gilead has previously indicated big-selling HIV drug Truvada wouldn't face generic competition until 2021. Now, Teva can launch next year, the company says.
Novo Nordisk has at least four more years to build up its newer diabetes drugs before they face Teva's versions of its $2.67B blockbuster Victoza.
FiercePharma’s most-read headlines of 2018 include industry themes that dominated the year's news or return time and again—and, of course, scandals.
AbbVie has inked a fourth patent deal on its megablockbuster Humira that forces Novartis to the back of the line for a U.S. launch.
Merck will pony up $625 million plus royalties on its blockbuster cancer med Keytruda to settle up its patent dispute with Opdivo-maker Bristol-Myers. The royalty stream could be "quite meaningful," one analyst said.
@FiercePharma: AZ's dental unit attracts a slew of suitors. Story | Follow @FiercePharma > Celgene has agreed to pay Elan $78 million to settle a patent infringement lawsuit over the Celgene